Company intelligence / Profile preview
Critical Pharmaceuticals
- Ownership
- Private
- Development stage
- Other
Overview
Critical Pharmaceuticals develops proprietary drug delivery platforms enabling sustained-release injectable depots and nasal formulations for biologics (proteins/peptides) and small molecules. The company has demonstrated technical feasibility through collaborations (e.g., with University of Nottingham on osteoporosis nano-spray) but does not have publicly disclosed late-stage clinical results or marketed products. Its pipeline appears focused on proof-of-concept studies supported by grants/collaborations rather than large-scale pivotal trials at this time.
- Therapeutic areas
- EndocrinologyOther
- Modalities
- ProteinPeptideSmall moleculeDNA-based therapy (including siRNA and aptamers)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Critical Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Critical Pharmaceuticals.